Clinical Trial Results
The information in this section provides Clinical Trial Results for interventional trials that were conducted on marketed products for which Bristol-Myers Squibb has disclosure responsibility. For more details, read our disclosure committment.
In compliance with the FDA Amendment Act of 2007, Bristol Myers Squibb has included adverse event (AE) and serious adverse event (SAE) information when disclosing clinical trial results from marketed products on the www.ClinicalTrials.gov website. The AE/SAE information contained on www.ClinicalTrials.gov represents data collected during the conduct of individual clinical trials. This information may not be indicative of the final aggregation of information included in the approved drug product label; therefore differences may exist between the data disclosed on www.ClinicalTrials.gov and the approved drug product label. The purpose of posting trial results is for disclosure and is not intended for aggregated analysis for signal detection purposes.
Please click on the product links to see the full prescribing information including Boxed WARNINGS for ABILIFY®, ATRIPLA®, BARACLUDE®, COUMADIN®, ERBITUX®, and Boxed WARNING for YERVOY™ regarding immune-mediated adverse reactions, and Boxed WARNINGS for AVAPRO® and AVALIDE® regarding use in pregnancy. As soon as pregnancy is detected, discontinue use of AVAPRO® or AVALIDE®.